Meghan J Chenoweth1,2, Jennifer J Ware3, Andy Z X Zhu1,2, Christopher B Cole4, Lisa Sanderson Cox5, Nikki Nollen5, Jasjit S Ahluwalia6, Neal L Benowitz7, Robert A Schnoll8, Larry W Hawk9, Paul M Cinciripini10, Tony P George11,12, Caryn Lerman13, Joanne Knight4, Rachel F Tyndale1,2,14. 1. Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. 2. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada. 3. MRC Integrative Epidemiology Unit (IEU) and School of Social and Community Medicine, University of Bristol, Bristol, UK. 4. Data Science Institute and Lancaster University Medical School, Lancaster, UK. 5. Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, KS, USA. 6. Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA. 7. Departments of Medicine and Bioengineering and Therapeutic Sciences, Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco, CA, USA. 8. Department of Psychiatry, Perelman School of Medicine, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. 9. Department of Psychology, University at Buffalo, SUNY, Buffalo, NY, USA. 10. Department of Behavioral Science, University of Texas, MD Anderson Cancer Center, Houston, TX, USA. 11. Division of Schizophrenia, Centre for Addiction and Mental Health, Toronto, ON, Canada. 12. Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 13. Department of Psychiatry, Annenberg School for Communication, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. 14. Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Abstract
BACKGROUND AND AIMS: The activity of CYP2A6, the major nicotine-inactivating enzyme, is measurable in smokers using the nicotine metabolite ratio (NMR; 3'hydroxycotinine/cotinine). Due to its role in nicotine clearance, the NMR is associated with smoking behaviours and response to pharmacotherapies. The NMR is highly heritable (~80%), and on average lower in African Americans (AA) versus whites. We previously identified several reduce and loss-of-function CYP2A6 variants common in individuals of African descent. Our current aim was to identify novel genetic influences on the NMR in AA smokers using genome-wide approaches. DESIGN: Genome-wide association study (GWAS). SETTING: Multiple sites within Canada and the United States. PARTICIPANTS: AA smokers from two clinical trials: Pharmacogenetics of Nicotine Addiction Treatment (PNAT)-2 (NCT01314001; n = 504) and Kick-it-at-Swope (KIS)-3 (NCT00666978; n = 450). MEASUREMENTS: Genome-wide SNP genotyping, the NMR (phenotype) and population substructure and NMR covariates. FINDINGS: Meta-analysis revealed three independent chromosome 19 signals (rs12459249, rs111645190 and rs185430475) associated with the NMR. The top overall hit, rs12459249 (P = 1.47e-39; beta = 0.59 per C (versus T) allele, SE = 0.045), located ~9.5 kb 3' of CYP2A6, remained genome-wide significant after controlling for the common (~10% in AA) non-functional CYP2A6*17 allele. In contrast, rs111645190 and rs185430475 were not genome-wide significant when controlling for CYP2A6*17. In total, 96 signals associated with the NMR were identified; many were not found in prior NMR GWASs in individuals of European descent. The top hits were also associated with the NMR in a third cohort of AA (KIS2; n = 480). None of the hits were in UGT or OCT2 genes. CONCLUSIONS: Three independent chromosome 19 signals account for ~20% of the variability in the nicotine metabolite ratio in African American smokers. The hits identified may contribute to inter-ethnic variability in nicotine metabolism, smoking behaviours and tobacco-related disease risk.
BACKGROUND AND AIMS: The activity of CYP2A6, the major nicotine-inactivating enzyme, is measurable in smokers using the nicotine metabolite ratio (NMR; 3'hydroxycotinine/cotinine). Due to its role in nicotine clearance, the NMR is associated with smoking behaviours and response to pharmacotherapies. The NMR is highly heritable (~80%), and on average lower in African Americans (AA) versus whites. We previously identified several reduce and loss-of-function CYP2A6 variants common in individuals of African descent. Our current aim was to identify novel genetic influences on the NMR in AA smokers using genome-wide approaches. DESIGN: Genome-wide association study (GWAS). SETTING: Multiple sites within Canada and the United States. PARTICIPANTS: AA smokers from two clinical trials: Pharmacogenetics of Nicotine Addiction Treatment (PNAT)-2 (NCT01314001; n = 504) and Kick-it-at-Swope (KIS)-3 (NCT00666978; n = 450). MEASUREMENTS: Genome-wide SNP genotyping, the NMR (phenotype) and population substructure and NMR covariates. FINDINGS: Meta-analysis revealed three independent chromosome 19 signals (rs12459249, rs111645190 and rs185430475) associated with the NMR. The top overall hit, rs12459249 (P = 1.47e-39; beta = 0.59 per C (versus T) allele, SE = 0.045), located ~9.5 kb 3' of CYP2A6, remained genome-wide significant after controlling for the common (~10% in AA) non-functional CYP2A6*17 allele. In contrast, rs111645190 and rs185430475 were not genome-wide significant when controlling for CYP2A6*17. In total, 96 signals associated with the NMR were identified; many were not found in prior NMR GWASs in individuals of European descent. The top hits were also associated with the NMR in a third cohort of AA (KIS2; n = 480). None of the hits were in UGT or OCT2 genes. CONCLUSIONS: Three independent chromosome 19 signals account for ~20% of the variability in the nicotine metabolite ratio in African American smokers. The hits identified may contribute to inter-ethnic variability in nicotine metabolism, smoking behaviours and tobacco-related disease risk.
Authors: Neal L Benowitz; Gary E Swan; Peyton Jacob; Christina N Lessov-Schlaggar; Rachel F Tyndale Journal: Clin Pharmacol Ther Date: 2006-11 Impact factor: 6.875
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: F Patterson; R A Schnoll; E P Wileyto; A Pinto; L H Epstein; P G Shields; L W Hawk; R F Tyndale; N Benowitz; C Lerman Journal: Clin Pharmacol Ther Date: 2008-04-02 Impact factor: 6.875
Authors: K Ikeda; K Yoshisue; E Matsushima; S Nagayama; K Kobayashi; C A Tyson; K Chiba; Y Kawaguchi Journal: Clin Cancer Res Date: 2000-11 Impact factor: 12.531
Authors: Yesha M Patel; Sunghim L Park; Younghun Han; Lynne R Wilkens; Heike Bickeböller; Albert Rosenberger; Neil Caporaso; Maria Teresa Landi; Irene Brüske; Angela Risch; Yongyue Wei; David C Christiani; Paul Brennan; Richard Houlston; James McKay; John McLaughlin; Rayjean Hung; Sharon Murphy; Daniel O Stram; Christopher Amos; Loïc Le Marchand Journal: Cancer Res Date: 2016-08-03 Impact factor: 12.701
Authors: Ellen M McDonagh; Catherine Wassenaar; Sean P David; Rachel F Tyndale; Russ B Altman; Michelle Whirl-Carrillo; Teri E Klein Journal: Pharmacogenet Genomics Date: 2012-09 Impact factor: 2.089
Authors: Alec W R Langlois; Ahmed El-Boraie; Koya Fukunaga; Taisei Mushiroda; Michiaki Kubo; Caryn Lerman; Jo Knight; Steven E Scherer; Meghan J Chenoweth; Rachel F Tyndale Journal: Pharmacogenet Genomics Date: 2022-02-21 Impact factor: 2.000
Authors: James W Baurley; Christopher S McMahan; Carolyn M Ervin; Bens Pardamean; Andrew W Bergen Journal: Trends Mol Med Date: 2018-02-04 Impact factor: 11.951
Authors: Haidy K Giratallah; Meghan J Chenoweth; Newton Addo; Jasjit S Ahluwalia; Lisa Sanderson Cox; Caryn Lerman; Tony P George; Neal L Benowitz; Rachel F Tyndale Journal: Drug Alcohol Depend Date: 2021-04-20 Impact factor: 4.852
Authors: Jadwiga Buchwald; Meghan J Chenoweth; Teemu Palviainen; Gu Zhu; Christian Benner; Scott Gordon; Tellervo Korhonen; Samuli Ripatti; Pamela A F Madden; Terho Lehtimäki; Olli T Raitakari; Veikko Salomaa; Richard J Rose; Tony P George; Caryn Lerman; Matti Pirinen; Nicholas G Martin; Jaakko Kaprio; Anu Loukola; Rachel F Tyndale Journal: Mol Psychiatry Date: 2020-03-10 Impact factor: 13.437